Clinical Research Protocols
Clinical Research Protocols for Endocrine Malignancies
Compiled by Margaret Gross-King, RN, MS, OCN
Clinical Research Manager, H. Lee Moffitt Cancer Center & Research Institute
This list of clinical research protocols relating to endocrine malignancies is compiled
for your convenience.
Thyroid Cancer
CAN-OTT-9401 NCI-V94-0566 Phase II Study of Cisplatin/Doxorubicin/Tamoxifen for
Incurable Soft Tissue and Endocrine Malignancies (Summary last modified 12/96).
Chairperson: S. Gertler, Ottawa Regional Cancer Centre-Civic Division, Ottawa, Ontario,
Canada. Lead organization: Ottawa Regional Cancer Centre-Civic Division. Acceptable age
range: 65 and under.
CMMI-C026 NCI-H95-0691 Phase I Study of 131I-Labeled Anti-CEA Antibody
Fragment MN-14 F(ab)2 for Advanced Medullary Thyroid Cancer (Summary last modified 07/96).
Chairperson: Malik Juweid, Center for Molecular Medicine and Immunology, Belleville,
NJ. Lead organization: Center for Molecular Medicine and Immunology. Acceptable age range:
18 and over.
CMMI-C026A NCI-V95-0692 Phase I/II Study of High-Dose 131I-Labeled Anti-CEA
Antibody Fragment MN-14 F(ab)2 Followed by Autologous Bone Marrow Rescue in Advanced
Medullary Thyroid Cancer (Summary last modified 07/96).
Chairperson: Malik Juweid, Center for Molecular Medicine and Immunology, Belleville,
NJ. Lead organization: Center for Molecular Medicine and Immunology. Acceptable age range:
16 and over.
UKMC-9540270 NCI-V96-0875 Phase II Study of a 96-Hour Continuous Infusion of TAX for
Anaplastic Carcinoma of the Thyroid Previously Untreated With Chemotherapy (Summary Last
Modified 09/96).
Chairperson: Kenneth Ain, Albert B. Chandler Medical Center, University of Kentucky,
Lexington, Ky. Lead organization: Albert B. Chandler Medical Center, University of
Kentucky. Acceptable age range: 18 and over.
Adrenocortical Carcinoma
CAN-OTT-9401 NCI-V94-0566 Phase II Study of Cisplatin/Doxorubicin/Tamoxifen for
Incurable Soft Tissue and Endocrine Malignancies (Summary last modified 12/96).
Chairperson: S. Gertler, Ottawa Regional Cancer Centre-Civic Division, Ottawa, Ontario,
Canada. Lead organization: Ottawa Regional Cancer Centre-Civic Division. Acceptable age
range: 65 and under.
NCI-93-C-0200A Phase II Study of Continuous-Infusion DOX/VCR/VP16 With Daily Oral
Mitotane Before and After Surgery in Patients With Adrenocortical Carcinoma (Summary last
modified 11/93).
Chairperson: Antonio Tito Fojo, National Cancer Institute, Bethesda, Md. Lead
organization: Division of Clinical Sciences. Acceptable age range: 18 and over.
Islet Cell Carcinoma
MAYO-924803 NCI-T92-0168D Phase II Study of Taxol in Patients With Advanced
Neuroendocrine Carcinoma (Summary last modified 06/96).
Chairperson: Joseph Rubin, Mayo Clinic, Rochester, Minn. Lead organization: Mayo
Clinical Cancer Center. Acceptable age range: over 18.
Carcinoid Tumors
E-9292 Phase II Study of IFN-gamma in Malignant Carcinoid Tumors (Summary last modified
04/96).
Chairperson: Tom Anderson, Director, Hematology/Oncology Program, Medical College of
Wisconsin, Milwaukee, Wisc. Lead organization: Eastern Cooperative Oncology Group.
Acceptable age range: 18 and over.
MAOP-5190 NCI-V90-0197 Phase II Pilot Study of Protracted Infusional 5-FU Plus
IFN-alpha for Advanced Metastatic Carcinoid Tumors (Summary last modified 04/96).
Chairperson: James D. Ahlgren, George Washington University Medical Center, Washington,
DC. Lead organization: Mid-Atlantic Oncology Program. Acceptable age range: 18 and over.
MAYO-924803 NCI-T92-0168D Phase II Study of Taxol in Patients With Advanced
Neuroendocrine Carcinoma (Summary last modified 06/96).
Chairperson: Joseph Rubin, Mayo Clinic, Rochester, Minn. Lead organization: Mayo
Clinical Cancer Center. Acceptable age range: over 18.
Legend for Abbreviations:
CAN-OTT = Ottawa Regional Cancer Center
CMMI = Center for Molecular Medicine and Immunology
E = Eastern Cooperative Oncology Group
MAOP = Mid-Atlantic Oncology Program
MAYO = Mayo Clinic
NCI = National Cancer Institute
UKMC = University of Kentucky Medical Center
For more information on these protocols, please call PDQ, a service of the National
Cancer Institute, at 1-800-4-CANCER.
Back to Cancer Control Journal
Volume 4 Number 1